FTCD

FTCD is a bifunctional enzyme (formiminotransferase-cyclodeaminase) that channels one-carbon units from histidine catabolism into folate metabolism; its two catalytic domains arose by fusion of distinct prokaryotic genes (PMID:10773664). Beyond its metabolic role, FTCD localizes to the Golgi complex and functions as a membrane-tethering factor by forming a large FTCD–p97/p47–FTCD complex via polyglutamate motifs, which is required for p97/p47-mediated post-mitotic Golgi reassembly (PMID:33555040). In hepatocytes, loss of FTCD depletes tetrahydrofolate and shifts the redox balance, and hepatocyte-specific knockout in mice activates the PTEN/Akt/mTOR–PPARγ/SREBP2 axis, promoting lipid accumulation and hepatocarcinogenesis (PMID:37675273, PMID:34774692).

1. 2000 Medium

   Cloning of human FTCD resolved the domain architecture of the bifunctional enzyme, establishing that the formiminotransferase and cyclodeaminase activities reside in a single polypeptide produced by an ancient prokaryotic gene fusion event.

   Evidence cDNA cloning, sequence analysis, and domain homology comparison with bacterial ORFs

   PMID:10773664

   Open questions at the time

   • No crystal structure of the human enzyme at that time
   • Enzymatic kinetics of each domain were not independently measured in this study
2. 2019 Medium

   A human-specific missense variant (p.Val101Met) in FTCD was linked to altered arsenic methylation efficiency, connecting FTCD's one-carbon/folate metabolic role to methyl-group supply in a population context.

   Evidence Exome-wide association study in 1,660 Bangladeshi individuals with Kozak sequence analysis

   PMID:30893314

   Open questions at the time

   • No in vitro enzymatic assay confirmed the variant's effect on FTCD catalytic activity
   • Single cohort; replication in independent populations not reported
   • Mechanism linking altered translation initiation to arsenic methylation not directly demonstrated
3. 2021 High

   FTCD was discovered to have a non-enzymatic structural role as a Golgi membrane-tethering factor, forming a large FTCD–p97/p47–FTCD complex through polyglutamate motifs that is essential for post-mitotic Golgi reassembly.

   Evidence Co-immunoprecipitation, in vitro Golgi reassembly assay, in vivo mitochondria-retargeting tethering assay, and fluorescence microscopy

   PMID:33555040

   Open questions at the time

   • Structural basis of FTCD–p47 interaction unresolved
   • Whether the enzymatic and tethering functions are coordinately regulated is unknown
   • Relevance of the tethering function in vivo (whole organism) not tested
4. 2021 Medium

   Re-expression of FTCD in HCC cells demonstrated that its enzymatic activity depletes tetrahydrofolate, collapses NADPH and glutathione redox buffering, and triggers mitochondrial cytochrome c release and caspase-dependent apoptosis, linking FTCD loss to a survival advantage in liver cancer.

   Evidence Overexpression in HCC cell lines with metabolite quantification (THF, NADPH/NADP+, GSH/GSSG), ROS assays, mitochondrial permeability assays, and xenograft model

   PMID:34774692

   Open questions at the time

   • Single-lab overexpression study; catalytic-dead mutant control not reported
   • Direct substrate channeling from formiminotransferase to cyclodeaminase domain not dissected
5. 2023 High

   Hepatocyte-specific Ftcd knockout in mice established a causal tumor-suppressive role: loss of FTCD activated PTEN/Akt/mTOR signaling and upregulated PPARγ/SREBP2, leading to lipid/cholesterol accumulation and both spontaneous and carcinogen-induced hepatocarcinogenesis.

   Evidence Liver-specific Ftcd knockout mice, diethylnitrosamine-induced HCC model, multi-omics (transcriptomics, metabolomics, proteomics), biochemical assays

   PMID:37675273

   Open questions at the time

   • Whether the Golgi-tethering function contributes to tumor suppression is unexplored
   • Direct molecular link between FTCD enzymatic product and PTEN regulation not identified
   • Human clinical validation of FTCD as a liver cancer biomarker or therapeutic target is lacking

• It remains unknown how FTCD's dual enzymatic and Golgi-tethering functions are coordinated, whether the two roles are independently regulated, and what the structural basis of the FTCD–p97/p47 tethering complex is.
• No structural model of the FTCD–p97/p47 complex
• No separation-of-function mutants distinguishing catalytic from tethering roles
• Tissue-specific regulation of the two functions not characterized